Adam Castano
Overview
Explore the profile of Adam Castano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
2040
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Judge D, Alexander K, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al.
J Am Coll Cardiol
. 2025 Mar;
85(10):1003-1014.
PMID: 40074465
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a...
2.
Razvi Y, Judge D, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, et al.
Circ Heart Fail
. 2024 Oct;
17(12):e012135.
PMID: 39465243
No abstract available.
3.
Castano A, Heitner S, Masri A, Huda A, Calambur V, Bruno M, et al.
J Card Fail
. 2023 Dec;
30(6):778-787.
PMID: 38065306
Background: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), an increasingly recognized cause of heart failure (HF), often remains undiagnosed until later stages of the disease. Methods And Results: A previously developed machine...
4.
Bourque J, Schepart A, Bhambri R, Castano A, OBrien A, Chen Y, et al.
Am J Cardiol
. 2022 Jan;
167:98-103.
PMID: 35022130
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is frequently misdiagnosed or diagnosed late in the disease course. ATTRwt-CM can be diagnosed invasively through tissue biopsy, but current diagnostic recommendations indicate technetium-99m pyrophosphate...
5.
Nativi-Nicolau J, Sarswat N, Fajardo J, Finkel M, Abdulsattar Y, Castano A, et al.
Clin Med Insights Cardiol
. 2021 Jun;
15:11795468211015230.
PMID: 34104028
Background: Because transthyretin amyloid cardiomyopathy (ATTR-CM) poses unique diagnostic and therapeutic challenges, referral of patients with known or suspected disease to specialized amyloidosis centers is recommended. These centers have developed...
6.
Friedman D, Goldberg J, Molinsky R, Hanson M, Castano A, Raza S, et al.
JMIR Cardio
. 2021 Jun;
5(1):e29101.
PMID: 34061037
Background: Patients with heart failure (HF) in skilled nursing facilities (SNFs) have 30-day hospital readmission rates as high as 43%. A virtual cardiovascular care program, consisting of patient selection, initial...
7.
Huda A, Castano A, Niyogi A, Schumacher J, Stewart M, Bruno M, et al.
Nat Commun
. 2021 May;
12(1):2725.
PMID: 33976166
Transthyretin amyloid cardiomyopathy, an often unrecognized cause of heart failure, is now treatable with a transthyretin stabilizer. It is therefore important to identify at-risk patients who can undergo targeted testing...
8.
Burton A, Castano A, Bruno M, Riley S, Schumacher J, Sultan M, et al.
Drug Des Devel Ther
. 2021 Mar;
15:1225-1243.
PMID: 33776421
Rare diseases are increasingly recognized as a global public health priority. Governments worldwide currently provide important incentives to stimulate the discovery and development of orphan drugs for the treatment of...
9.
Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges
Bruno M, Castano A, Burton A, Grodin J
Heart Fail Rev
. 2020 Aug;
26(1):35-45.
PMID: 32794090
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease characterized by deposition of insoluble amyloid fibrils in the myocardium, resulting in cardiac structural and functional abnormalities and ultimately heart failure....
10.
Rosenblum H, Masri A, Narotsky D, Goldsmith J, Hamid N, Hahn R, et al.
Eur J Heart Fail
. 2020 Jul;
23(2):250-258.
PMID: 32729170
Aims: Advances in diagnostic imaging have increased the recognition of coexisting transthyretin cardiac amyloidosis (ATTR-CA) and severe aortic stenosis (AS), with a reported prevalence between 8-16%. In this prospective study,...